Milrinon Stragen (Milrinone)

Milrinone selectively blocks phosphodiesterase‑3, which raises intracellular cAMP levels. Higher cAMP enhances calcium entry into heart muscle cells, producing stronger contractions, while also relaxing vascular smooth muscle, leading to vasodilation and reduced afterload.

The dosing regimen for Milrinon Stragen is determined by the treating physician based on the patient’s clinical status, weight, renal function, and response. Only a qualified prescriber may set the infusion rate and duration.

Safety data for milrinone in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is generally reserved for situations where the potential benefit outweighs any possible risk, and only under specialist supervision.

To request Milrinon Stragen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Milrinone differs from catecholamine inotropes such as dopamine or dobutamine by acting through phosphodiesterase‑3 inhibition rather than adrenergic receptors. This mechanism provides both inotropic support and vasodilation, which can be advantageous in patients with high systemic vascular resistance, but it may also increase the risk of hypotension.

Milrinon Stragen must be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial. Do not use if the solution appears discolored or contains particles.

Milrinon Stragen is supplied as an intravenous solution and is given by controlled infusion through a dedicated IV line. Administration is performed by trained healthcare professionals in a monitored setting, with dosing adjustments based on hemodynamic response.

The most critical risks include severe hypotension, life‑threatening ventricular arrhythmias, and myocardial ischemia. Continuous cardiac and blood pressure monitoring is essential to detect these events early and intervene appropriately.

Milrinon Stragen is contraindicated in patients with uncontrolled ventricular arrhythmias, severe hypotension unresponsive to treatment, or known hypersensitivity to milrinone or any formulation component. Caution is also advised in recent myocardial infarction or severe renal impairment.